{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:36:21Z","timestamp":1783600581917,"version":"3.55.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>As part of the Novartis Signature Program, this study evaluated the efficacy of ribociclib (selective cyclin-dependent kinase 4\/6 [CDK4\/6] inhibitor) in patients with cyclin D\u2013CDK4\/6 pathway\u2013aberrant tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>\n              This was a phase II, single-arm, signal-seeking study in patients with advanced malignancies that had progressed on or after standard treatment. Prior identification of tumor\n              <jats:italic>CDK4\/6<\/jats:italic>\n              mutation or amplification,\n              <jats:italic>CCND1<\/jats:italic>\n              \/3 amplification, or\n              <jats:italic>CDKN2A<\/jats:italic>\n              mutation or loss was required. Clinical benefit (defined as the proportion of patients with response or stable disease at \u2265 16 weeks) was the primary end point.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>From 61 centers in the United States, 106 patients (median age, 62.5 years) were enrolled across multiple malignancies. The patient population was heavily pretreated (median number of prior therapies, three; range, 0 to 19). Median progression-free survival was 1.8 months (95% CI, 1.8 to 1.9). In patients with solid tumors, the clinical benefit rate was 18.1% (n = 19 of 105) and the overall response rate was 2.9% (n = 3 of 105); three partial responses occurred in patients with adenocarcinoma (unknown primary), soft tissue sarcoma, and urothelial carcinoma. No tumor cohort met the prespecified criteria for success. The most common adverse events suspected to be related to treatment were neutropenia (30.2%; decreased neutrophils, 15.1%), fatigue (31.1%), and nausea (29.2%). Fatigue and nausea were typically mild. Only one incident of febrile neutropenia was experienced (grade 3).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>\n              No new or unexpected safety signals were observed in this heavily pretreated patient population. Although responses were seen in tumors with\n              <jats:italic>CCND1<\/jats:italic>\n              \u2013\n              <jats:italic>CDK4\/6<\/jats:italic>\n              amplifications, the primary end point was not met, suggesting additional evaluation of ribociclib, possibly as combination therapy, is needed.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po.18.00383","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T19:55:13Z","timestamp":1565985313000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":15,"title":["Tissue\/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D\u2013CDK4\/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study"],"prefix":"10.1200","author":[{"given":"Julio","family":"Peguero","sequence":"first","affiliation":[{"name":"Oncology Consultants PA, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davendra P. S.","family":"Sohal","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert H.","family":"O\u2019Neil","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Safran","sequence":"additional","affiliation":[{"name":"Rhode Island Hospital, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[{"name":"University of California, Davis Comprehensive Cancer Center, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juneko E.","family":"Grilley-Olson","sequence":"additional","affiliation":[{"name":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lincoln","family":"Nadauld","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare, St George, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Das","family":"Purkayastha","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Stealey","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro D.","family":"Ricart","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barinder P.","family":"Kang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Paul","family":"Eder","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0816"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1014149"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81401-4"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25511"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.126"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510062"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25109"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.2007"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0462"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.814"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2413"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9751"},{"key":"e_1_3_5_16_2","unstructured":"US Food and Drug Administration: FDA approves first cancer treatment for any solid tumor with a specific genetic feature. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm560167.htm"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0909"},{"key":"e_1_3_5_18_2","unstructured":"US Food and Drug Administration: Praxis Extended RAS Panel. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/P160038B.pdf"},{"key":"e_1_3_5_19_2","unstructured":"US Food and Drug Administration: FDA grants marketing approval to FoundationOne CDx in vitro diagnostic. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm587387.htm"},{"key":"e_1_3_5_20_2","unstructured":"US Food and Drug Administration: Physician Insert: Oncomine Dx Target Test. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/p160045d.pdf"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0095"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.08.003"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0264"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","unstructured":"Edelman MJ Redman MW Albain KS et al: A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. J Clin Oncol 35 2017 (15 suppl; abstr 9056)","DOI":"10.1200\/JCO.2017.35.15_suppl.9056"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918786451"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.12.035"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26215"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.18.00383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T17:12:23Z","timestamp":1727629943000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.18.00383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1200\/PO.18.00383"],"URL":"https:\/\/doi.org\/10.1200\/po.18.00383","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"2019-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}